Results 221 to 230 of about 146,147 (346)

1833 QUINACRINE INHIBITS ARACHIDONIC-ACID INDUCED PULMONAR VASOCONSTRICTION [PDF]

open access: bronze, 1985
Jav R Shavevitz   +2 more
openalex   +1 more source

Glucocorticoids and HPA axis regulation in the stress–obesity connection: A comprehensive overview of biological, physiological and behavioural dimensions

open access: yesClinical Obesity, Volume 15, Issue 2, April 2025.
Summary Chronic stress, characterized by increased long‐term exposure to the glucocorticoid hormone cortisol, is increasingly linked to obesity development. Still, various knowledge gaps persist, including on underlying pathophysiological mechanisms. The aim of the current review is to provide the latest insights on the connection between stress and ...
Robin Lengton   +4 more
wiley   +1 more source

Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator Reversing Hypoxic Pulmonary Vasoconstriction

open access: yesCirculation, 1991
Claes Frostell   +4 more
semanticscholar   +1 more source

Role of Histone Deacetylase and Inhibitors in Cardiovascular Diseases

open access: yesCell Proliferation, EarlyView.
HDACs play an important role in the occurrence and development of cardiovascular diseases, such as myocardial hypertrophy, hypertension, and atherosclerosis. HDAC inhibitors have broad prospects for the treatment of CVD, and different HDAC subtypes can act through different mechanisms.
Li‐Ying Zhang   +4 more
wiley   +1 more source

DEPRESSION OF HYPOXIC PULMONARY VASOCONSTRICTION BY SODIUM NITROPRUSSIDE AND NITROGLYCERINE

open access: bronze, 1981
Marcelo Silveira D'Oliveira   +4 more
openalex   +1 more source

Long‐term preservation of kidney function with SGLT‐2 inhibitors versus comparator drugs in people with type 2 diabetes and chronic kidney disease

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Chronic kidney disease (CKD) is a prevalent and serious complication of type 2 diabetes (T2D). This study aims to evaluate kidney outcomes in a real‐world cohort of patients with T2D and CKD who received SGLT2 inhibitors (SGLT2i) or other glucose‐lowering medications (GLM).
Gian Paolo Fadini   +87 more
wiley   +1 more source

Home - About - Disclaimer - Privacy